Oct 20, 2015 6:30 am EDT Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
Oct 05, 2015 7:00 am EDT Atara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet
Oct 05, 2015 6:30 am EDT Atara Bio’s Collaborating Investigators to Present Data at the American Society of Nephrology Kidney Week 2015
Sep 24, 2015 6:30 am EDT Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
Sep 02, 2015 6:40 pm EDT Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in September 2015
Aug 31, 2015 6:30 am EDT Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting
Jul 15, 2015 11:24 am EDT Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares